Champions Oncology Stock Analysis
CSBR Stock | USD 5.03 0.20 3.82% |
Champions Oncology is undervalued with Real Value of 6.03 and Target Price of 8.75. The main objective of Champions Oncology stock analysis is to determine its intrinsic value, which is an estimate of what Champions Oncology is worth, separate from its market price. There are two main types of Champions Oncology's stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Champions Oncology's performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Champions Oncology's stock to identify patterns and trends that may indicate its future price movements.
The Champions Oncology stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Champions Oncology is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Champions Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Champions Oncology's ongoing operational relationships across important fundamental and technical indicators.
Champions |
Champions Stock Analysis Notes
About 26.0% of the company shares are held by company insiders. The company has Price/Earnings (P/E) ratio of 220.0. Champions Oncology recorded a loss per share of 0.72. The entity had not issued any dividends in recent years. The firm had 1:12 split on the 12th of August 2015. Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey. Champions Oncolog operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 230 people. For more info on Champions Oncology please contact Joel Ackerman at 201 808 8400 or go to https://www.championsoncology.com.Champions Oncology Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Champions Oncology's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Champions Oncology or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Champions Oncology generated a negative expected return over the last 90 days | |
The company reported the previous year's revenue of 53.87 M. Net Loss for the year was (5.33 M) with profit before overhead, payroll, taxes, and interest of 24.34 M. | |
About 26.0% of the company shares are held by company insiders | |
Latest headline from finance.yahoo.com: Will Champions Oncology Spend Its Cash Wisely |
Champions Oncology Upcoming and Recent Events
Earnings reports are used by Champions Oncology to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Champions Oncology previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
20th of March 2024 Upcoming Quarterly Report | View | |
22nd of July 2024 Next Financial Report | View | |
31st of January 2024 Next Fiscal Quarter End | View | |
22nd of July 2024 Next Fiscal Year End | View | |
31st of October 2023 Last Quarter Report | View | |
30th of April 2023 Last Financial Announcement | View |
Champions Largest EPS Surprises
Earnings surprises can significantly impact Champions Oncology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2020-12-14 | 2020-10-31 | 0.0067 | 1.0E-4 | -0.0066 | 98 | ||
2022-12-13 | 2022-10-31 | -0.01 | -0.0012 | 0.0088 | 88 | ||
2021-12-13 | 2021-10-31 | 0.01 | 0.02 | 0.01 | 100 |
Champions Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Champions Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Champions Oncology backward and forwards among themselves. Champions Oncology's institutional investor refers to the entity that pools money to purchase Champions Oncology's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Bank Of New York Mellon Corp | 2023-12-31 | 30.8 K | Acadian Asset Management Llc | 2023-12-31 | 30.7 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 26.8 K | State Street Corporation | 2023-12-31 | 26.6 K | Bank Of America Corp | 2023-12-31 | 25.8 K | Aristides Capital Llc | 2023-12-31 | 11.8 K | Citadel Advisors Llc | 2023-09-30 | 10.9 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 9.1 K | Ubs Group Ag | 2023-12-31 | 2.2 K | Battery Management Corp | 2023-09-30 | 2.4 M | Nea Management Company, Llc | 2023-12-31 | 1.7 M |
Champions Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 68.85 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Champions Oncology's market, we take the total number of its shares issued and multiply it by Champions Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Champions Profitablity
Champions Oncology's profitability indicators refer to fundamental financial ratios that showcase Champions Oncology's ability to generate income relative to its revenue or operating costs. If, let's say, Champions Oncology is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Champions Oncology's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Champions Oncology's profitability requires more research than a typical breakdown of Champions Oncology's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (0.2) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.21) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.21. Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.14) | (0.15) | |
Return On Capital Employed | (0.32) | (0.33) | |
Return On Assets | (0.14) | (0.15) | |
Return On Equity | (1.32) | (1.39) |
Management Efficiency
Champions Oncology has return on total asset (ROA) of (0.1748) % which means that it has lost $0.1748 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.8865) %, meaning that it created substantial loss on money invested by shareholders. Champions Oncology's management efficiency ratios could be used to measure how well Champions Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/19/2024, Return On Tangible Assets is likely to drop to -0.15. In addition to that, Return On Capital Employed is likely to drop to -0.33. At this time, Champions Oncology's Total Assets are relatively stable compared to the past year. As of 04/19/2024, Non Current Assets Total is likely to grow to about 17.9 M, while Intangible Assets are likely to drop slightly above 650.6 K.Last Reported | Projected for Next Year | ||
Book Value Per Share | 0.39 | 0.46 | |
Net Current Asset Value | 0.00 | 0.00 | |
Tangible Asset Value | 0.00 | 0.00 | |
Tangible Book Value Per Share | 0.32 | 0.37 | |
Enterprise Value Over EBITDA | (52.96) | (50.32) | |
Price Book Value Ratio | 16.33 | 17.14 | |
Enterprise Value Multiple | (52.96) | (50.32) | |
Price Fair Value | 16.33 | 17.14 | |
Enterprise Value | 57.9 M | 43.6 M |
The analysis of Champions Oncology's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Champions Oncology's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Champions Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.398 |
Technical Drivers
As of the 19th of April, Champions Oncology shows the risk adjusted performance of (0.08), and Mean Deviation of 2.15. Champions Oncology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed thirteen technical drivers for Champions Oncology, which can be compared to its peers. Please confirm Champions Oncology risk adjusted performance, variance, as well as the relationship between the Variance and potential upside to decide if Champions Oncology is priced correctly, providing market reflects its regular price of 5.03 per share. Given that Champions Oncology has information ratio of (0.16), we suggest you to validate Champions Oncology's prevailing market performance to make sure the company can sustain itself at a future point.Champions Oncology Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Champions Oncology middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Champions Oncology. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Champions Oncology Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Champions Oncology insiders, such as employees or executives, is commonly permitted as long as it does not rely on Champions Oncology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Champions Oncology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Daniel Mendelson few days ago Acquisition by Daniel Mendelson of 500 shares of Champions Oncology at 5.83 subject to Rule 16b-3 | ||
Daniel Mendelson over two weeks ago Disposition of 34375 shares by Daniel Mendelson of Champions Oncology at 5.76 subject to Rule 16b-3 | ||
Scott Tobin over three weeks ago Acquisition by Scott Tobin of 10000 shares of Champions Oncology at 3.21 subject to Rule 16b-3 | ||
David Sidransky over three months ago Acquisition by David Sidransky of 15495 shares of Champions Oncology subject to Rule 16b-3 | ||
David Sidransky over six months ago Acquisition by David Sidransky of 11480 shares of Champions Oncology subject to Rule 16b-3 |
Champions Oncology Predictive Daily Indicators
Champions Oncology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Champions Oncology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Champions Oncology Corporate Filings
F4 | 1st of April 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 15th of March 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 12th of March 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 12th of February 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
F4 | 16th of January 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 12th of January 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 11th of January 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 10th of January 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Champions Oncology Forecast Models
Champions Oncology's time-series forecasting models are one of many Champions Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Champions Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Champions Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Champions Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Champions shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Champions Oncology. By using and applying Champions Stock analysis, traders can create a robust methodology for identifying Champions entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.11) | (0.12) | |
Operating Profit Margin | (0.1) | (0.1) | |
Net Loss | (0.11) | (0.12) | |
Gross Profit Margin | 0.52 | 0.53 |
Current Champions Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Champions analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Champions analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
8.75 | Hold | 1 | Odds |
Most Champions analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Champions stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Champions Oncology, talking to its executives and customers, or listening to Champions conference calls.
Champions Stock Analysis Indicators
Champions Oncology stock analysis indicators help investors evaluate how Champions Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Champions Oncology shares will generate the highest return on investment. By understating and applying Champions Oncology stock analysis, traders can identify Champions Oncology position entry and exit signals to maximize returns.
Begin Period Cash Flow | 9 M | |
Total Stockholder Equity | 4.6 M | |
Capital Lease Obligations | 8.6 M | |
Property Plant And Equipment Net | 14.5 M | |
Cash And Short Term Investments | 10.1 M | |
Cash | 10.1 M | |
50 Day M A | 5.439 | |
Total Current Liabilities | 21.7 M | |
Forward Price Earnings | 22.8833 | |
Investments | -2.9 M | |
Common Stock Total Equity | 14 K | |
Stock Based Compensation | 864 K | |
Common Stock Shares Outstanding | 13.5 M | |
Total Cashflows From Investing Activities | -2.9 M | |
Tax Provision | 68 K | |
Quarterly Earnings Growth Y O Y | -0.286 | |
Other Current Assets | 1.3 M | |
Accounts Payable | 5.3 M | |
Net Debt | -1.5 M | |
Other Operating Expenses | 58.3 M | |
Non Current Assets Total | 14.9 M | |
Liabilities And Stockholders Equity | 34.3 M | |
Non Currrent Assets Other | 15 K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.Note that the Champions Oncology information on this page should be used as a complementary analysis to other Champions Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Complementary Tools for Champions Stock analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Champions Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Champions Oncology. If investors know Champions will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Champions Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.29) | Earnings Share (0.72) | Revenue Per Share 3.634 | Quarterly Revenue Growth (0.06) | Return On Assets (0.17) |
The market value of Champions Oncology is measured differently than its book value, which is the value of Champions that is recorded on the company's balance sheet. Investors also form their own opinion of Champions Oncology's value that differs from its market value or its book value, called intrinsic value, which is Champions Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Champions Oncology's market value can be influenced by many factors that don't directly affect Champions Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Champions Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Champions Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Champions Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.